Protein Science, Vol 7, Issue 11 2249-2255, Copyright © 1998 by Cold Spring Harbor Laboratory Press

ARTICLE

A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase

T. FOX, J. T. COLL, X. XIE, P. J. FORD, U. A. GERMANN, M. D. PORTER, S. PAZHANISAMY, M. A. FLEMING, V. GALULLO, MSS. SU and K. P. WILSON
Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts 02139-4242

Mitogen-activated protein (MAP) kinases are serine/threonine kinases that mediate intracellular signal transduction pathways. Pyridinyl imidazole compounds block pro-inflammatory cytokine production and are specific p38 kinase inhibitors. ERK2 is related to p38 in sequence and structure, but is not inhibited by pyridinyl imidazole inhibitors. Crystal structures of two pyridinyl imidazoles complexed with p38 revealed these compounds bind in the ATP site. Mutagenesis data suggested a single residue difference at threonine 106 between p38 and other MAP kinases is sufficient to confer selectivity of pyridinyl imidazoles. We have changed the equivalent residue in human ERK2, Q105, into threonine and alanine, and substituted four additional ATP binding site residues. The single residue change Q105A in ERK2 enhances the binding of SB202190 at least 25,000-fold compared to wild-type ERK2. We report enzymatic analyses of wild-type ERK2 and the mutant proteins, and the crystal structure of a pyridinyl imidazole, SB203580, bound to an ERK2 pentamutant, I103L, Q105T, D106H, E109G, T110A. These ATP binding site substitutions induce low nanomolar sensitivity to pyridinyl imidazoles. Furthermore, we identified 5-iodotubercidin as a potent ERK2 inhibitor, which may help reveal the role of ERK2 in cell proliferation.
CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. Mayer, B. Wulffen, C. Huber, J. Brockmann, B. Flicke, L. Neumann, D. Hafenbradl, B. M. Klebl, M. J. Lohse, C. Krasel, et al. An RNA molecule that specifically inhibits G-protein-coupled receptor kinase 2 in vitro RNA, March 1, 2008; 14(3): 524 - 534. [Abstract] [Full Text] [PDF]

				S. J. O'Keefe, J. S. Mudgett, S. Cupo, J. N. Parsons, N. A. Chartrain, C. Fitzgerald, S.-L. Chen, K. Lowitz, C. Rasa, D. Visco, et al. Chemical Genetics Define the Roles of p38{alpha} and p38 in Acute and Chronic Inflammation J. Biol. Chem., November 30, 2007; 282(48): 34663 - 34671. [Abstract] [Full Text] [PDF]

				M. A. Emrick, T. Lee, P. J. Starkey, M. C. Mumby, K. A. Resing, and N. G. Ahn The gatekeeper residue controls autoactivation of ERK2 via a pathway of intramolecular connectivity PNAS, November 28, 2006; 103(48): 18101 - 18106. [Abstract] [Full Text] [PDF]

				B. Baan, H. van Dam, G. C. M. van der Zon, J. A. Maassen, and D. M. Ouwens The Role of c-Jun N-Terminal Kinase, p38, and Extracellular Signal-Regulated Kinase in Insulin-Induced Thr69 and Thr71 Phosphorylation of Activating Transcription Factor 2 Mol. Endocrinol., August 1, 2006; 20(8): 1786 - 1795. [Abstract] [Full Text] [PDF]

				M. Jacobs, K. Hayakawa, L. Swenson, S. Bellon, M. Fleming, P. Taslimi, and J. Doran The Structure of Dimeric ROCK I Reveals the Mechanism for Ligand Selectivity J. Biol. Chem., January 6, 2006; 281(1): 260 - 268. [Abstract] [Full Text] [PDF]

				I. S. Lucet, E. Fantino, M. Styles, R. Bamert, O. Patel, S. E. Broughton, M. Walter, C. J. Burns, H. Treutlein, A. F. Wilks, et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor Blood, January 1, 2006; 107(1): 176 - 183. [Abstract] [Full Text] [PDF]

				T. A. Carter, L. M. Wodicka, N. P. Shah, A. M. Velasco, M. A. Fabian, D. K. Treiber, Z. V. Milanov, C. E. Atteridge, W. H. Biggs III, P. T. Edeen, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases PNAS, August 2, 2005; 102(31): 11011 - 11016. [Abstract] [Full Text] [PDF]

				M. S. Willis, J. K. Hogan, P. Prabhakar, X. Liu, K. Tsai, Y. Wei, and T. Fox Investigation of protein refolding using a fractional factorial screen: A study of reagent effects and interactions Protein Sci., July 1, 2005; 14(7): 1818 - 1826. [Abstract] [Full Text] [PDF]

				M. D. Jacobs, J. Black, O. Futer, L. Swenson, B. Hare, M. Fleming, and K. Saxena Pim-1 Ligand-bound Structures Reveal the Mechanism of Serine/Threonine Kinase Inhibition by LY294002 J. Biol. Chem., April 8, 2005; 280(14): 13728 - 13734. [Abstract] [Full Text] [PDF]

				M. Gassel, C. B. Breitenlechner, N. Konig, R. Huber, R. A. Engh, and D. Bossemeyer The Protein Kinase C Inhibitor Bisindolyl Maleimide 2 Binds with Reversed Orientations to Different Conformations of Protein Kinase A J. Biol. Chem., May 28, 2004; 279(22): 23679 - 23690. [Abstract] [Full Text] [PDF]

				F. Gambelli, P. Di, X. Niu, M. Friedman, T. Hammond, D. W. H. Riches, and L. A. Ortiz Phosphorylation of Tumor Necrosis Factor Receptor 1 (p55) Protects Macrophages from Silica-induced Apoptosis J. Biol. Chem., January 16, 2004; 279(3): 2020 - 2029. [Abstract] [Full Text] [PDF]

				A. N. Hoofnagle, J. W. Stoner, T. Lee, S. S. Eaton, and N. G. Ahn Phosphorylation-Dependent Changes in Structure and Dynamics in ERK2 Detected by SDSL and EPR Biophys. J., January 1, 2004; 86(1): 395 - 403. [Abstract] [Full Text] [PDF]

				J. P. Headrick, B. Hack, and K. J. Ashton Acute adenosinergic cardioprotection in ischemic-reperfused hearts Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H1797 - H1818. [Abstract] [Full Text] [PDF]

				N. R. Mahapatra, M. Mahata, D. T. O'Connor, and S. K. Mahata Secretin Activation of Chromogranin A Gene Transcription: IDENTIFICATION OF THE SIGNALING PATHWAYS IN CIS AND IN TRANS J. Biol. Chem., May 23, 2003; 278(22): 19986 - 19994. [Abstract] [Full Text] [PDF]

				C. H. Gross, J. D. Parsons, T. H. Grossman, P. S. Charifson, S. Bellon, J. Jernee, M. Dwyer, S. P. Chambers, W. Markland, M. Botfield, et al. Active-Site Residues of Escherichia coli DNA Gyrase Required in Coupling ATP Hydrolysis to DNA Supercoiling and Amino Acid Substitutions Leading to Novobiocin Resistance Antimicrob. Agents Chemother., March 1, 2003; 47(3): 1037 - 1046. [Abstract] [Full Text] [PDF]

				J. Peart, L. Willems, and J. P. Headrick Receptor and non-receptor-dependent mechanisms of cardioprotection with adenosine Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H519 - H527. [Abstract] [Full Text] [PDF]

				G. M. T. Cheetham, R. M. A. Knegtel, J. T. Coll, S. B. Renwick, L. Swenson, P. Weber, J. A. Lippke, and D. A. Austen Crystal Structure of Aurora-2, an Oncogenic Serine/Threonine Kinase J. Biol. Chem., November 1, 2002; 277(45): 42419 - 42422. [Abstract] [Full Text] [PDF]

				T. L.-Y. Chang, C. J. Gordon, B. Roscic-Mrkic, C. Power, A. E. I. Proudfoot, J. P. Moore, and A. Trkola Interaction of the CC-Chemokine RANTES with Glycosaminoglycans Activates a p44/p42 Mitogen-Activated Protein Kinase-Dependent Signaling Pathway and Enhances Human Immunodeficiency Virus Type 1 Infectivity J. Virol., March 1, 2002; 76(5): 2245 - 2254. [Abstract] [Full Text] [PDF]

				G. Pearson, F. Robinson, T. Beers Gibson, B.-e Xu, M. Karandikar, K. Berman, and M. H. Cobb Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions Endocr. Rev., April 1, 2001; 22(2): 153 - 183. [Abstract] [Full Text]

				A. N. Hoofnagle, K. A. Resing, E. J. Goldsmith, and N. G. Ahn Changes in protein conformational mobility upon activation of extracellular regulated protein kinase-2 as detected by hydrogen exchange PNAS, January 30, 2001; 98(3): 956 - 961. [Abstract] [Full Text] [PDF]